TCF7L2 and colorectal carcinoma: We observed significantly higher sensitivity to dasatinib in CRC cell lines with mutations in TCF7L2, CTNNB1 or APC, and AXIN1, which is another WNT pathway component, when compared with WNT pWT cell lines (Fig 5D).